GLPwatch

A Study Comparing the Injection Site Pain Experience After the Injection of Semaglutide B and Semaglutide D With 2 Different Injection Pens, a Compound for the Treatment of Type 2 Diabetes and Obesity

NCT04143945 · Completed

Last updated 2026-05-28

This clinical trial compares the pain at the injection site when using two different forms of semaglutide (B and D) with two different injection pens in healthy volunteers and those with type 2 diabetes, overweight, or obesity.

Status Completed The study has finished.
Phase Phase 2 Tests whether it works and watches safety in a moderate group.
Type Interventional (clinical trial)
Design Randomized, quadruple-blind treatment study
Participants 104 people
Who can join Ages 18–75 · all sexes Healthy volunteers accepted.
Timeline Started 2019-10 · est. completion 2020-01
Where 1 site · Netherlands

What this study is testing ClinicalTrials.gov NCT04143945 ↗

Description as written by the study sponsor.

This study in healthy men and women looks at the injection site experience of the DV3396 pen to that of the PDS290 pens when both pens are used to deliver 0.25 mg semaglutide subcutaneously (s.c., under the skin). Participants will receive 2 single doses of semaglutide 0.25 mg on 1 day. The 2 injections will be given at least 30 minutes apart, one in each side of the stomach. Participants will be in the clinic research center for 1 day. A follow-up phone call will take place between 4 and 5 weeks after the injections were given.

Treatments tested

Main thing measuredIntensity of Injection Site Pain
SponsorNovo Nordisk A/S
Conditions studiedHealthy Volunteers Diabetes Mellitus, Type 2, Healthy Volunteers Overweight, Healthy Volunteers Obesity
GLP-1 drugs semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04143945 ↗